We are live on ! Find out more
ADIL

Adial Pharmaceuticals
ADIL

19 hedge funds and large institutions have $477K invested in Adial Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.01% → 0.01% (-0%)

14% less funds holding

Funds holding: 22 → 19 (-3)

44% less capital invested

Capital invested by funds: $847K → $477K (-$369K)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
19
Holders Change
-3
Holders Change %
-13.64%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Creative Planning
Creative Planning
Kansas
+$2.89K
2
Renaissance Technologies
Renaissance Technologies
New York
+$1.81K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$362
4
Osaic Holdings
Osaic Holdings
Arizona
+$181

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$12.3K
2
Brown Advisory
Brown Advisory
Maryland
-$9.11K
3
BlackRock
BlackRock
New York
-$9.04K
4
EWM
Empirical Wealth Management
Washington
-$8.75K
5
TSS
Two Sigma Securities
New York
-$8.13K
Name Holding Trade Value Shares
Change 		Change in
Stake
MCM
1
Manchester Capital Management
Vermont
$250K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$42.3K – – –
BlackRock
3
BlackRock
New York
$40.5K -$9.04K -50 -14%
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$37.5K -$12.3K -68 -19%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$28.6K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$22K +$1.81K +10 +6%
State Street
7
State Street
Massachusetts
$10.9K – – –
Commonwealth Equity Services
8
Commonwealth Equity Services
Massachusetts
$8K – – –
Truist Financial
9
Truist Financial
North Carolina
$7.05K – – –
Northern Trust
10
Northern Trust
Illinois
$6.18K – – –
VF
11
Virtu Financial
New York
$6K -$5.79K -32 -43%
Osaic Holdings
12
Osaic Holdings
Arizona
$5K +$181 +1 +3%
TSS
13
Two Sigma Securities
New York
$4.31K -$8.13K -45 -58%
Two Sigma Investments
14
Two Sigma Investments
New York
$3.67K – – –
Envestnet Asset Management
15
Envestnet Asset Management
Illinois
$2.73K – – –
Creative Planning
16
Creative Planning
Kansas
$2.08K +$2.89K +16 New
Morgan Stanley
17
Morgan Stanley
New York
$111 – – –
Wells Fargo
18
Wells Fargo
California
$39 -$181 -1 Closed
Brown Advisory
19
Brown Advisory
Maryland
– -$9.11K -42 Closed
EWM
20
Empirical Wealth Management
Washington
– -$8.75K -40 Closed
UBS Group
21
UBS Group
Switzerland
– -$3.72K -17 Closed
Simplex Trading
22
Simplex Trading
Illinois
– -$723 -4 Closed
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
– +$362 +2 New

ADIL Hedge Fund Activity: Q2 2023 in Review

19 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2023, worth a combined $477K — down 44% from $847K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ADIL and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Creative Planning, opening a new position worth an estimated $2.89K. The largest seller was Susquehanna International Group, cutting an estimated $12.3K.

  • 19 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2023, down from 22 in Q1 2023.
  • Funds reported $477K of Adial Pharmaceuticals stock for Q2 2023, down 44% quarter-over-quarter.
  • 2 funds opened new Adial Pharmaceuticals positions in Q2 2023 and 5 closed out, a net change of -3 holders.
  • The largest Adial Pharmaceuticals buyer in Q2 2023 was Creative Planning, an estimated $2.89K added.
  • The largest Adial Pharmaceuticals seller in Q2 2023 was Susquehanna International Group, an estimated $12.3K sold.

Based on aggregated 13F filings for Q2 2023.